Xeris Biopharma (NASDAQ:XERS) Stock Price Expected to Rise, HC Wainwright Analyst Says

Xeris Biopharma (NASDAQ:XERS) had its price target raised by HC Wainwright from $6.00 to $6.60 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Xeris Biopharma’s Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.41) EPS, FY2025 earnings at ($0.29) EPS, FY2026 earnings at ($0.03) EPS, FY2027 earnings at $0.19 EPS and FY2028 earnings at $0.51 EPS.

Separately, Piper Sandler cut Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Monday.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $3.05 on Monday. Xeris Biopharma has a 1 year low of $1.46 and a 1 year high of $3.64. The business has a 50 day moving average price of $3.00 and a 200 day moving average price of $2.53. The company has a market capitalization of $454.70 million, a P/E ratio of -6.78 and a beta of 2.70.

Institutional Trading of Xeris Biopharma

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Xeris Biopharma by 7.3% during the 1st quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after purchasing an additional 519,897 shares during the period. SG Americas Securities LLC lifted its position in Xeris Biopharma by 188.5% during the third quarter. SG Americas Securities LLC now owns 60,202 shares of the company’s stock worth $172,000 after buying an additional 39,335 shares during the period. Simplicity Wealth LLC acquired a new stake in Xeris Biopharma in the 2nd quarter worth about $27,000. Bayesian Capital Management LP purchased a new stake in Xeris Biopharma in the 1st quarter valued at about $37,000. Finally, Renaissance Technologies LLC increased its stake in shares of Xeris Biopharma by 33.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after acquiring an additional 342,300 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.